Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.X4 Pharmaceuticals (XFOR) Reports Q3 Loss, Tops Revenue Estimates
X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026
4 Biotech Stocks Seeing Unusual Options Volume Today
X4 Pharmaceuticals, Inc. (XFOR) Analyst/Investor Day Transcript
X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day
X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia
Head to Head Review: Entrada Therapeutics (NASDAQ:TRDA) versus X4 Pharmaceuticals (NASDAQ:XFOR)
X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Rated “Moderate Buy” by Sell-Side Brokerages
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Down 25.4% in 4 Weeks, Here's Why X4 Pharmaceuticals (XFOR) Looks Ripe for a Turnaround
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $11.25 Consensus Price Target from Brokerages
X4 Pharmaceuticals (XFOR) Loses 20.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update